Derek Archila
Stock Analyst at Wells Fargo
(3.80)
# 753
Out of 4,711 analysts
163
Total ratings
45.95%
Success rate
9.75%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Overweight | $639 → $723 | $623.82 | +15.90% | 10 | Dec 19, 2024 | |
| ZYME Zymeworks | Maintains: Equal-Weight | $12 → $14 | $14.14 | -0.99% | 5 | Dec 19, 2024 | |
| KZR Kezar Life Sciences | Maintains: Equal-Weight | $11 → $9 | $6.38 | +41.07% | 11 | Dec 19, 2024 | |
| INCY Incyte | Maintains: Equal-Weight | $68 → $70 | $68.84 | +1.69% | 6 | Dec 19, 2024 | |
| IMVT Immunovant | Maintains: Overweight | $47 → $45 | $25.86 | +74.01% | 9 | Dec 19, 2024 | |
| CABA Cabaletta Bio | Downgrades: Equal-Weight | $12 → $6 | $2.38 | +152.10% | 8 | Dec 19, 2024 | |
| CCCC C4 Therapeutics | Upgrades: Overweight | $8 → $12 | $3.95 | +203.80% | 5 | Dec 19, 2024 | |
| GLUE Monte Rosa Therapeutics | Downgrades: Equal-Weight | $14 → $11 | $6.93 | +58.73% | 4 | Dec 19, 2024 | |
| VRDN Viridian Therapeutics | Downgrades: Equal-Weight | $27 | $19.03 | +41.88% | 1 | Dec 19, 2024 | |
| ANAB AnaptysBio | Maintains: Overweight | $56 → $40 | $14.55 | +174.91% | 2 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $13 | $3.15 | +312.70% | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $95 → $16 | $3.59 | +345.68% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $38 → $57 | $40.66 | +40.19% | 7 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $43 | $24.28 | +77.10% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $24 | $4.00 | +500.00% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $43 → $30 | $33.21 | -9.67% | 10 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $151 | $90.14 | +67.52% | 8 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $36 | $33.29 | +8.14% | 2 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $3.35 | +407.46% | 1 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $264 → $289 | $136.38 | +111.91% | 13 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $11 | $2.24 | +391.07% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $25.14 | +47.18% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $29 → $9 | $3.00 | +200.00% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $5.23 | +91.20% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $60 | $18.48 | +224.68% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $52 | $56.12 | -7.34% | 4 | Apr 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $19.83 | +0.86% | 4 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $2.19 | +813.24% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.35 | +665.96% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $3.80 | - | 1 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $26.76 | +621.23% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $100.08 | -59.03% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $24 → $8 | $0.46 | +1,639.13% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $3.19 | +1,780.88% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $4.78 | +506.69% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.58 | +3,064.56% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $10.64 | +379.32% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $25.75 | +241.75% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $18.98 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $22.09 | - | 2 | Aug 3, 2017 |
argenx SE
Dec 19, 2024
Maintains: Overweight
Price Target: $639 → $723
Current: $623.82
Upside: +15.90%
Zymeworks
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $14.14
Upside: -0.99%
Kezar Life Sciences
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $6.38
Upside: +41.07%
Incyte
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $68 → $70
Current: $68.84
Upside: +1.69%
Immunovant
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $25.86
Upside: +74.01%
Cabaletta Bio
Dec 19, 2024
Downgrades: Equal-Weight
Price Target: $12 → $6
Current: $2.38
Upside: +152.10%
C4 Therapeutics
Dec 19, 2024
Upgrades: Overweight
Price Target: $8 → $12
Current: $3.95
Upside: +203.80%
Monte Rosa Therapeutics
Dec 19, 2024
Downgrades: Equal-Weight
Price Target: $14 → $11
Current: $6.93
Upside: +58.73%
Viridian Therapeutics
Dec 19, 2024
Downgrades: Equal-Weight
Price Target: $27
Current: $19.03
Upside: +41.88%
AnaptysBio
Dec 12, 2024
Maintains: Overweight
Price Target: $56 → $40
Current: $14.55
Upside: +174.91%
Dec 11, 2024
Maintains: Overweight
Price Target: $15 → $13
Current: $3.15
Upside: +312.70%
Dec 11, 2024
Downgrades: Equal-Weight
Price Target: $95 → $16
Current: $3.59
Upside: +345.68%
Dec 2, 2024
Upgrades: Overweight
Price Target: $38 → $57
Current: $40.66
Upside: +40.19%
Nov 19, 2024
Initiates: Overweight
Price Target: $43
Current: $24.28
Upside: +77.10%
Nov 15, 2024
Maintains: Overweight
Price Target: $44 → $24
Current: $4.00
Upside: +500.00%
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $43 → $30
Current: $33.21
Upside: -9.67%
Oct 31, 2024
Maintains: Overweight
Price Target: $153 → $151
Current: $90.14
Upside: +67.52%
Oct 30, 2024
Maintains: Overweight
Price Target: $32 → $36
Current: $33.29
Upside: +8.14%
Oct 4, 2024
Initiates: Overweight
Price Target: $17
Current: $3.35
Upside: +407.46%
Sep 17, 2024
Maintains: Overweight
Price Target: $264 → $289
Current: $136.38
Upside: +111.91%
Aug 12, 2024
Maintains: Overweight
Price Target: $16 → $11
Current: $2.24
Upside: +391.07%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $25.14
Upside: +47.18%
Jun 18, 2024
Downgrades: Equal-Weight
Price Target: $29 → $9
Current: $3.00
Upside: +200.00%
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $5.23
Upside: +91.20%
May 9, 2024
Maintains: Overweight
Price Target: $63 → $60
Current: $18.48
Upside: +224.68%
Apr 18, 2024
Maintains: Overweight
Price Target: $53 → $52
Current: $56.12
Upside: -7.34%
Feb 16, 2024
Maintains: Overweight
Price Target: $23 → $20
Current: $19.83
Upside: +0.86%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $2.19
Upside: +813.24%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $2.35
Upside: +665.96%
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $3.80
Upside: -
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $26.76
Upside: +621.23%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $100.08
Upside: -59.03%
Mar 31, 2020
Maintains: Hold
Price Target: $24 → $8
Current: $0.46
Upside: +1,639.13%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $3.19
Upside: +1,780.88%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $4.78
Upside: +506.69%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.58
Upside: +3,064.56%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $10.64
Upside: +379.32%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $25.75
Upside: +241.75%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $18.98
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $22.09
Upside: -